Opportunity Information: Apply for HT942524PCARPTRPA
The FY24 DOD Pancreatic Cancer, Translational Research Partnership Award (HT942524PCARPTRPA) is a discretionary grant program run by the Department of the Army through USAMRAA under CFDA 12.420. Its main purpose is to speed up the translation of promising pancreatic cancer discoveries into practical clinical use by funding true, two-way collaborations between a clinician investigator and a research scientist. The program is designed for projects that are harder to accomplish when the clinical and laboratory efforts are separated, and it places heavy emphasis on a shared, intellectually balanced partnership rather than a one-sided arrangement where one party simply provides samples, patients, or access.
A defining requirement is that the application must be led by two independent Principal Investigators who contribute equally to the scientific design and execution of the project. One PI is designated the Initiating PI and typically handles most of the administrative steps for submission, while the other is the Partnering PI. If funded, each PI is named on a separate award issued to the relevant organization(s), and each award comes with its own reporting and compliance responsibilities. In practice, this structure signals that both partners are expected to be fully accountable and deeply engaged throughout the work, not just consulted occasionally.
The award is specifically oriented toward translational research, meaning the project must show a reciprocal flow of ideas and information between basic science and clinical practice. The expectation is not simply "bench to bedside" or "bedside to bench" in one direction, but an iterative cycle where clinical observations shape laboratory experiments and laboratory findings are tested, refined, and validated using clinically meaningful data, specimens, or interventions. Competitive proposals typically explain exactly how clinical information will be used to close knowledge gaps, interpret outcomes, validate key findings, extend potentially transformative results, and/or pursue new observations that emerge during the study. Correlative studies are explicitly allowable, and proposals may involve the development or use of annotated biorepositories, as long as the clinical and scientific components are tightly integrated and mutually informative.
The program strongly encourages convergence science partnerships, which generally means bringing together distinct disciplines, methods, or technologies in a coordinated way to tackle complex problems. While at least one partner must have direct expertise either in pancreatic cancer research or pancreatic cancer patient care, the opportunity also welcomes experts from outside the pancreatic cancer field if their skills meaningfully strengthen the translational strategy. That openness is meant to help teams bring in capabilities such as advanced engineering, computational methods, novel imaging, immunology, chemistry, or other specialized approaches, as long as the work remains centered on a key pancreatic cancer question with a realistic pathway toward clinical relevance.
In terms of scope, the award is not intended to fully support large-scale clinical trials. However, it does allow several clinically connected approaches, including retrospective tissue analyses, correlative studies, and small pilot clinical trials. The emphasis is on credible near-term movement toward clinical application across the pancreatic cancer continuum, including prevention, diagnosis, detection, prognosis, treatment, and survivorship. Applicants are expected to clearly state why the proposed effort could materially influence pancreatic cancer research and/or patient care and how it could accelerate the adoption of promising ideas into real-world clinical settings.
Feasibility is a major review theme. Applications should demonstrate that the team has access to the necessary specimens, datasets, clinical populations, and/or interventions required to complete the proposed work. Just as important, the submission must include concrete plans for how the partners will work together across labs, clinics, and institutions, including communication routines, coordination of progress, sharing of results, and data transfer processes. For multi-institutional collaborations, an intellectual property plan is required to address potential IP or material transfer barriers that could otherwise slow down cooperation and derail the translational goals.
Preliminary data are required and must be relevant to pancreatic cancer and the proposed project, whether published or unpublished, from the PIs or named collaborators. The program also requires preliminary evidence that supports the feasibility of the hypotheses and research approaches, but it gives teams flexibility by allowing those feasibility-supporting data to come from outside pancreatic cancer if they still convincingly de-risk the core methods or mechanisms being proposed. The solicitation also recognizes that strong translational ideas can originate from several sources, including laboratory discoveries, population-based analyses, and clinician-driven insights that come from firsthand experience with patients and real-world observations.
Finally, while the ultimate aim is to advance outcomes relevant to active-duty Service Members, Veterans, other military beneficiaries, and the broader American public, the operational hallmark of this mechanism is the quality of the clinician-scientist partnership. The project must clearly depend on the unique strengths of each partner, demonstrate genuine intellectual synergy, and show a practical, believable plan for moving a pancreatic cancer concept closer to clinical use. The original closing date listed for this opportunity is October 3, 2024, with an unrestricted eligible applicant pool and an expected number of awards listed as 4.Apply for HT942524PCARPTRPA
- The Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DOD Pancreatic Cancer, Translational Research Partnership Award" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
- This funding opportunity was created on 2024-04-29.
- Applicants must submit their applications by 2024-10-03. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The number of recipients for this funding is limited to 4 candidate(s).
- Eligible applicants include: Unrestricted.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FY24 DOD Pancreatic Cancer Translational Research Partnership Award (HT942524PCARPTRPA) - FAQs
What is the FY24 DOD Pancreatic Cancer, Translational Research Partnership Award?
It is a discretionary grant program run by the Department of the Army through USAMRAA under CFDA 12.420. The award is designed to speed up the translation of promising pancreatic cancer discoveries into practical clinical use by funding true, two-way collaborations between a clinician investigator and a research scientist.
What is the main goal of this award?
The main goal is to accelerate movement of pancreatic cancer discoveries toward clinical application by supporting projects that are difficult to accomplish when clinical and laboratory work are separated, and by requiring a genuinely balanced clinician-scientist partnership.
What makes this program different from a typical collaboration?
This program places heavy emphasis on a shared, intellectually balanced partnership. It is not intended to support a one-sided arrangement where one partner only supplies samples, patients, or access while the other partner drives the science.
How many Principal Investigators (PIs) are required?
Two independent Principal Investigators are required, and they must contribute equally to the scientific design and execution of the project.
What are the roles of the Initiating PI and Partnering PI?
One PI is designated as the Initiating PI and typically handles most of the administrative steps for submission. The other PI is the Partnering PI. Both are expected to be fully accountable and deeply engaged throughout the project.
How are awards issued if the application is funded?
If funded, each PI is named on a separate award issued to the relevant organization(s). Each award has its own reporting and compliance responsibilities, reinforcing that both partners share responsibility for the work.
What type of research is this award meant to support?
The award is oriented toward translational pancreatic cancer research with an iterative, two-way flow of ideas and information between basic science and clinical practice, rather than a one-directional "bench to bedside" or "bedside to bench" approach.
What does "two-way" translational research mean in this context?
It means clinical observations should shape laboratory experiments, and laboratory findings should be tested, refined, and validated using clinically meaningful data, specimens, or interventions. The expectation is an iterative cycle rather than a single handoff.
What elements do competitive translational proposals typically explain?
Competitive proposals typically explain how clinical information will be used to close knowledge gaps, interpret outcomes, validate key findings, extend potentially transformative results, and/or pursue new observations that emerge during the study.
Are correlative studies allowed?
Yes. Correlative studies are explicitly allowable under this award.
Can a project involve an annotated biorepository?
Yes. Proposals may involve development or use of annotated biorepositories, as long as the clinical and scientific components are tightly integrated and mutually informative.
Does the award encourage convergence science partnerships?
Yes. The program strongly encourages convergence science partnerships, meaning teams can bring together distinct disciplines, methods, or technologies in a coordinated way to address complex pancreatic cancer problems.
Do the investigators need to be pancreatic cancer specialists?
At least one partner must have direct expertise either in pancreatic cancer research or pancreatic cancer patient care. The other partner may come from outside the pancreatic cancer field if their expertise strengthens the translational strategy.
Can experts from outside pancreatic cancer apply as part of the team?
Yes. Experts outside the pancreatic cancer field are welcomed when their skills (for example, engineering, computational methods, imaging, immunology, chemistry, or other specialized approaches) meaningfully strengthen the translational plan and the work remains centered on a key pancreatic cancer question with a realistic path to clinical relevance.
Is this award intended to support large-scale clinical trials?
No. The award is not intended to fully support large-scale clinical trials.
What clinically connected study types are allowed?
The opportunity allows several clinically connected approaches, including retrospective tissue analyses, correlative studies, and small pilot clinical trials.
What areas of the pancreatic cancer continuum can be addressed?
The program emphasizes near-term movement toward clinical application across prevention, diagnosis, detection, prognosis, treatment, and survivorship.
What is expected regarding clinical relevance and impact?
Applicants are expected to clearly state why the proposed work could materially influence pancreatic cancer research and/or patient care and how it could accelerate adoption of promising ideas into real-world clinical settings.
How important is feasibility in the review?
Feasibility is a major review theme. Applications should show access to needed specimens, datasets, clinical populations, and/or interventions and provide practical plans for carrying out the work.
What collaboration planning details should be included in the application?
The application should include concrete plans for how partners will work together across labs, clinics, and institutions, including communication routines, progress coordination, sharing of results, and data transfer processes.
Is an intellectual property (IP) plan required?
For multi-institutional collaborations, an IP plan is required to address potential intellectual property or material transfer barriers that could slow down cooperation and derail translational goals.
Are preliminary data required?
Yes. Preliminary data are required and must be relevant to pancreatic cancer and the proposed project. These data may be published or unpublished and may come from the PIs or named collaborators.
Can feasibility-supporting preliminary evidence come from outside pancreatic cancer?
Yes. The program allows feasibility-supporting data from outside pancreatic cancer if they convincingly de-risk the core methods or mechanisms proposed, even though the project itself must be centered on pancreatic cancer.
What kinds of sources can spark a strong translational idea for this award?
The solicitation recognizes that strong translational ideas can come from laboratory discoveries, population-based analyses, and clinician-driven insights based on firsthand patient care experience and real-world observations.
Who is the ultimate beneficiary population for this research?
The ultimate aim is to advance outcomes relevant to active-duty Service Members, Veterans, other military beneficiaries, and the broader American public.
What is described as the operational hallmark of this funding mechanism?
The hallmark is the quality of the clinician-scientist partnership, including clear dependence on each partner's unique strengths, genuine intellectual synergy, and a believable plan to move a pancreatic cancer concept closer to clinical use.
Who is eligible to apply?
The eligible applicant pool is listed as unrestricted.
How many awards are expected to be made?
The expected number of awards is 4.
What is the closing date for this opportunity?
The original closing date listed is October 3, 2024.
What identifier is associated with this opportunity?
The opportunity is identified as the FY24 DOD Pancreatic Cancer, Translational Research Partnership Award with the identifier HT942524PCARPTRPA.
Which agency administers the program?
The program is run by the Department of the Army through USAMRAA.
What CFDA number is associated with this program?
The opportunity is listed under CFDA 12.420.
Browse more opportunities from the same category: Science and Technology and other Research and Development
Next opportunity: Fiscal Year 2024 State Fire Training Systems Grant
Previous opportunity: Advancing HIV service delivery through pharmacies and pharmacists (R21 Clinical Trial Optional)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for HT942524PCARPTRPA
Applicants also applied for:
Applicants who have applied for this opportunity (HT942524PCARPTRPA) also looked into and applied for these:
| Funding Opportunity |
|---|
| Award Competition for Hollings Manufacturing Extension Partnership (MEP) Center in the State of Florida Apply for 2024 NIST MEP 01 Funding Number: 2024 NIST MEP 01 Agency: National Institute of Standards and Technology Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Prostate Cancer, Data Science Award Apply for HT942524PCRPDSA Funding Number: HT942524PCRPDSA Agency: Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Scientific Ocean Drilling Coordination Office (SODCO) for the Division of Ocean Sciences Apply for 24 568 Funding Number: 24 568 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Peer Reviewed Cancer, Patient Well-Being and Survivorship Award Apply for HT942524PRCRPPWSA Funding Number: HT942524PRCRPPWSA Agency: Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Peer Reviewed Cancer, Career Development Award- Scholar Option Apply for HT942524PRCRPCDASO Funding Number: HT942524PRCRPCDASO Agency: Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Peer Reviewed Cancer, Impact Award Apply for HT942524PRCRPIPA Funding Number: HT942524PRCRPIPA Agency: Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Peer Reviewed Cancer, Idea Award Apply for HT942524PRCRPIA Funding Number: HT942524PRCRPIA Agency: Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Prostate Cancer, Physician Research Award Apply for HT942524PCRPPRA Funding Number: HT942524PCRPPRA Agency: Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Prostate Cancer, Early Investigator Research Award Apply for HT942524PCRPEIRA Funding Number: HT942524PCRPEIRA Agency: Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Prostate Cancer, Exploration - Hypothesis Development Award Apply for HT942524PCRPEHDA Funding Number: HT942524PCRPEHDA Agency: Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Prostate Cancer, Idea Development Award Apply for HT942524PCRPIDA Funding Number: HT942524PCRPIDA Agency: Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Mathematical Foundations of Artificial Intelligence Apply for 24 569 Funding Number: 24 569 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: $1,500,000 |
| Cooperative Agreement for CESU-affiliated Partner with the Gulf Coast Cooperative Ecosystem Studies Unit Apply for G24AS00358 Funding Number: G24AS00358 Agency: Geological Survey Category: Science and Technology and other Research and Development Funding Amount: $150,000 |
| PILCEE Apply for 7200AA24RFA00013 Funding Number: 7200AA24RFA00013 Agency: Agency for International Development Category: Science and Technology and other Research and Development Funding Amount: $74,900,000 |
| Public Wireless Supply Chain Innovation Fund Grant Program - Open Radio Commercialization and Innovation Apply for NTIA PWSCIF 24 01 Funding Number: NTIA PWSCIF 24 01 Agency: National Institute of Standards and Technology Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Cooperative Agreement for CESU-affiliated Partner with Great Lakes – Northern Forest Cooperative Ecosystem Studies Unit Apply for G24AS00361 Funding Number: G24AS00361 Agency: Geological Survey Category: Science and Technology and other Research and Development Funding Amount: $132,796 |
| Cooperative Agreement for CESU-affiliated Partner with Rocky Mountain Cooperative Ecosystem Studies Unit Apply for G24AS00362 Funding Number: G24AS00362 Agency: Geological Survey Category: Science and Technology and other Research and Development Funding Amount: $39,657 |
| Cooperative Agreement for CESU-affiliated Partner with the Gulf Coast Cooperative Ecosystem Studies Unit Apply for G24AS00357 Funding Number: G24AS00357 Agency: Geological Survey Category: Science and Technology and other Research and Development Funding Amount: $33,000 |
| DoD Prostate Cancer, Implementation Science Award Apply for HT942524PCRPISA Funding Number: HT942524PCRPISA Agency: Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DOD Duchenne Muscular Dystrophy, Idea Development Award Apply for HT942524DMDRPIDA Funding Number: HT942524DMDRPIDA Agency: Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "HT942524PCARPTRPA", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.